As quantum technology and artificial intelligence move toward precision medicine, regulators face a problem they have not yet built tools for. A Brief Quantum Medicine Policy Guide—published on the Harvard Petrie-Flom Center's Bill of Health blog by Mauritz Kop, Suzan Slijpen, Katie Liu, Jin-Hee Lee, Constanze Albrecht, and I. Glenn Cohen, and cross-posted with the Stanford Center for Responsible Quantum Technology and the European Commission's European AI Alliance—is a concise map of the use cases, the overlapping legal regimes, and what agencies such as the FDA and EMA should consider. It is a companion to the team's longer treatment of how quantum technologies may be integrated into healthcare, and continues the collaboration later reflected in Kop's work consulting Amgen on quantum biomedical discovery.
Quantum use cases in healthcare
The guide sorts second-generation quantum medicine by domain. Quantum computing and simulation could accelerate de novo drug discovery by modeling molecular interactions, speed genome sequencing, and assist protein-folding prediction; quantum sensing could deliver continuous high-precision vital-sign monitoring, precision laser therapy, and earlier retinal diagnostics; post-quantum cryptography and quantum key distribution could secure patient data in line with HIPAA and GDPR. A recurring thread is the semiconducting quantum dot, whose ability to cross the blood-brain barrier opens possibilities in oncology imaging, targeted drug delivery, and neurodegenerative-disease research. Throughout, the authors keep the claims proportionate, marking many applications as early-stage or theoretical.
A fragmented regulatory map
There is no quantum-specific medical-device law in either the EU or the US. European devices fall mainly under the Medical Devices Regulation, with the EU AI Act and data laws in supporting roles, while CE marking is slowed by a shortage of Notified Bodies versed in AI or quantum. US devices may sit within the existing FDA framework—potentially including the Software-as-a-Medical-Device pathway—alongside HIPAA, the FTC, and standards such as ISO 13485. The guide's first practical counsel is for manufacturers to engage agencies early.
What regulators should build next
The guide names four changes: evaluation protocols attuned to quantum behaviors; risk-management frameworks that protect human subjects from quantum unpredictability; clinical-trial guidelines tailored to quantum devices; and interoperability standards. It then proposes a three-part architecture—ex-ante regulatory sandboxes for quantum-AI devices, ex-durante expert subcommittees, and an ex-post registration database—framed by ten guiding principles, from promoting quantum literacy to fostering institutional plasticity in bodies like the FDA and EMA. The throughline is a standards-first, anticipatory posture: prepare the institutions before the technology arrives, and balance innovation against patient safety rather than choosing between them.
Meer lezen